human osteosarcoma cell line saos 2  (ATCC)

Journal: Drug Delivery

Article Title: Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma

doi: 10.1080/10717544.2026.2671485

Figure Lengend Snippet: Antitumor effect of organometallic compounds in osteosarcoma cell lines. Cell viability (WST-1 assay) in 2D cultures measured after the treatment of 143B Par (A), OS833 Par (B), 143B CisPt-R (C), and OS833 CisPt-R (D) with increasing concentrations of free or encapsulated drugs for 72 h. The effect of equivalent amounts of empty nanoparticles in each cell line is shown. IC 50 values for each treatment are indicated. Error bars represent the standard deviation of three independent experiments. Asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon) (**** p < 0.0001; two-way ANOVA Tukey's test). (E and F) Analysis of DNA damage (formation of −H2AX foci) in 143B CisPt-R cells treated with the IC 75 of CisPt (8.4 µM), Ru3 (0.9 µM), LIP-Ru3 (0.8 µM), or the equivalent amount of empty nanoparticles (LIP-Empty) for 24 hours. Representative images of immunofluorescence staining (scale bar = 25 µm) (E) and quantification of the formation of gH2AX foci in >100 cells (F) are shown. Asterisks indicate statistically significant differences (** p < 0.01; *** p < 0.001; One-way ANOVA Tukey's test). (G) Cell cycle distribution of 143B CisPt-R cells treated with the IC 50 of CisPt (5 µM), Ru3 (0.5 µM), LIP-Ru3 (0.5 µM), or the equivalent amount of empty nanoparticles (LIP-Empty) for 48 hours. The normalized percentage of cells in each cell cycle phase (mean ± standard deviation of three independent experiments) is shown. Asterisks indicate statistically significant differences in G 0 /G 1 phase (blue) between LIP-empty control and Ru3-formulations and in the G 2 /M phase (pink) between LIP-empty and CisPt (**** p < 0.0001; two-way ANOVA Tukey's test).

Article Snippet: Human osteosarcoma cell line 143B (CRL-8303) was obtained from the ATCC repository (Manassas, VA, USA).

Techniques: WST-1 Assay, Standard Deviation, Immunofluorescence, Staining, Control

Journal: Drug Delivery

Article Title: Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma

doi: 10.1080/10717544.2026.2671485

Figure Lengend Snippet: Cytotoxic effect of organometallic compounds in 3D parental spheroids. Spheroid viability (CTG 3D assay) was measured after the treatment of 143B Par (A and B) and OS833 Par (C and D) spheroids with increasing concentrations of free and encapsulated drugs for 96 h. The effect of equivalent amounts of empty nanoparticles is shown. Representative images of 143B Par (A) and OS833 Par (C) spheroids treated with increasing concentrations of each compound are shown (scale bars = 250 µm). Likewise, cell survival curves and IC50 values (µM) for each condition in 143B Par (B) and OS833 Par (D) spheroids are presented as the mean ± the standard deviation of at least eight biological replicates. Asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon) (**** p < 0.0001; two-way ANOVA Tukey's test).

Article Snippet: Human osteosarcoma cell line 143B (CRL-8303) was obtained from the ATCC repository (Manassas, VA, USA).

Techniques: Standard Deviation

Journal: Drug Delivery

Article Title: Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma

doi: 10.1080/10717544.2026.2671485

Figure Lengend Snippet: Cytotoxic effect of organometallic compounds in 3D cisplatin-resistant spheroids. Spheroid viability (CTG 3D assay) was measured after the treatment of 143B CisPt-R (A and B) and OS833 CisPt-R (C and D) spheroids with increasing concentrations of free and encapsulated drugs for 96 h. The effect of equivalent amounts of empty nanoparticles is shown. Representative images of 143B CisPt-R (A) and OS833 CisPt-R (C) spheroids treated with increasing concentrations of each compound are shown (scale bars = 250 µm). Cell survival curves and IC50 values (µM) for each condition in 143B CisPt-R (B) and OS833 CisPt-R (D) are presented as the mean ± standard deviation of at least eight biological replicates. Asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon) (* p < 0.05; ** p < 0.01; **** p < 0.0001; two-way ANOVA Tukey's test).

Article Snippet: Human osteosarcoma cell line 143B (CRL-8303) was obtained from the ATCC repository (Manassas, VA, USA).

Techniques: Standard Deviation

Journal: Drug Delivery

Article Title: Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma

doi: 10.1080/10717544.2026.2671485

Figure Lengend Snippet: Effect of free and nano-encapsulated Ru3 in CSC-enriched 3D osteosarcoma cell cultures. 143B Par cells were plated at low density in tumorsphere medium and left to form tumorspheres for 9 days before being treated for 96 h with increasing concentrations of Ru3, LIP-Ru3, and cisplatin. Treatments with the same amount of empty nanoparticles (LIP-Empty) were also included. Representative images (scale bars = 250 μm) (A), quantification of the number of tumorspheres remaining after the treatment (B), and cell viability (WST-1 assay) (C) are presented. Data is presented as the mean ± the standard deviation of independent replicates. In panel B, black asterisks indicate statistically significant differences between controls and the indicated conditions in each treatment. In panel C, asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon); (** p < 0.01; *** p < 0.001; one-way (panel B) or two-way (panel C) ANOVA Tukey's test).

Article Snippet: Human osteosarcoma cell line 143B (CRL-8303) was obtained from the ATCC repository (Manassas, VA, USA).

Techniques: WST-1 Assay, Standard Deviation

Journal: Drug Delivery

Article Title: Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma

doi: 10.1080/10717544.2026.2671485

Figure Lengend Snippet: In vivo antitumor effect of free and nanoencapsulated metallic compounds. Established 143B CisPt-R xenografts were randomly assigned to six different groups ( n = 5 per group) and treated i.v. with vehicle (PBS, control), empty liposomes (LIP-Empty), free Ru3 (4 mg/kg, Ru3), ruthenium-loaded liposomes (4 mg/kg, LIP-Ru3), RAPTA-C (4 mg/kg), and cisplatin (4 mg/kg) once a week for 3 weeks (cumulative dose of 12 mg/kg). (A) Curves representing the mean relative tumor volume of 143B CisPt-R xenografts during the treatments. Drug efficacy expressed as the percentage of TGI is indicated. (B) Average tumor weight (left panel) and images of the tumors (right panel) at the end of the experiment (day 20 after the start of the treatment). (C) Change in the body weights of mice during the treatments. Error bars represent the SEM and asterisks indicate statistically significant differences between groups (* p < 0.05; **** p < 0.0001, two-way ANOVA Tukey's test).

Article Snippet: Human osteosarcoma cell line 143B (CRL-8303) was obtained from the ATCC repository (Manassas, VA, USA).

Techniques: In Vivo, Control, Liposomes